- Home
- ALXO vs TLSA Comparison
ALXO vs TLSA Comparison
Compare ALXO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- TLSA
- Stock Information
- Founded
- ALXO 2015
- TLSA 2013
- Country
- ALXO United States
- TLSA United Kingdom
- Employees
- ALXO N/A
- TLSA N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- TLSA Health Care
- Exchange
- ALXO Nasdaq
- TLSA Nasdaq
- Market Cap
- ALXO 76.5M
- TLSA 87.8M
- IPO Year
- ALXO 2020
- TLSA 2000
- Fundamental
- Price
- ALXO $1.74
- TLSA $0.74
- Analyst Decision
- ALXO Buy
- TLSA
- Analyst Count
- ALXO 6
- TLSA 0
- Target Price
- ALXO $11.00
- TLSA N/A
- AVG Volume (30 Days)
- ALXO 1.1M
- TLSA 442.0K
- Earning Date
- ALXO 03-06-2025
- TLSA 01-28-2025
- Dividend Yield
- ALXO N/A
- TLSA N/A
- EPS Growth
- ALXO N/A
- TLSA N/A
- EPS
- ALXO N/A
- TLSA N/A
- Revenue
- ALXO N/A
- TLSA N/A
- Revenue This Year
- ALXO N/A
- TLSA N/A
- Revenue Next Year
- ALXO N/A
- TLSA N/A
- P/E Ratio
- ALXO N/A
- TLSA N/A
- Revenue Growth
- ALXO N/A
- TLSA N/A
- 52 Week Low
- ALXO $1.19
- TLSA $0.41
- 52 Week High
- ALXO $17.83
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- ALXO 53.13
- TLSA 44.91
- Support Level
- ALXO $1.56
- TLSA $0.68
- Resistance Level
- ALXO $1.94
- TLSA $0.80
- Average True Range (ATR)
- ALXO 0.16
- TLSA 0.08
- MACD
- ALXO -0.01
- TLSA 0.01
- Stochastic Oscillator
- ALXO 50.00
- TLSA 34.34
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.